Roche Diagnostics UK & Ireland

The journey for a patient with cognitive decline is often one of ambiguity and waiting. For clinicians, the challenge is finding a clear path forward. What if one simple blood test could cut through the uncertainty? Our pTau181 assay is designed to do just that. With a single result, you can stratify patients in two crucial ways—helping to identify those with or without a negative result.¹,²,³. This clarity empowers you to have more definitive conversations and guide families toward the right care plan with greater confidence. By simplifying the science, we empower the human connection at the heart of medicine. 1 Roche. (2025). Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease. (Press Release, July 23, 2025). 2 News-Medical. (2024). Plasma pTau181 predicts Alzheimer's progression in real-world memory clinic patients. (Accessed July 25, 2025). 3 Canestaro, W. J., et al. (2024). Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment. Population health management, 27(3), 174 184.

Are you navigating the evolving landscape of dementia diagnostics? The Roche Neurology Learning Hub provides UK healthcare professionals with evidence-based resources, KOL interviews, case studies and patient perspectives on neurological diagnositics.

The cobas® i 601 is a fully automated mass spec analyser, which Tiago Sousa at SWLP describes as "revolutionary". Watch how it transforms the lab's morning routine - just do maintenance, top up reagents, run QCs, and it’s ready to go and deliver patient results.

Workflow efficiency isn't just about speed; it's about capacity. With the cobas® i 601 analyser handling routine tests, and delivering shorter turnaround times, SWLP can reallocate staff time to specialised testing. For Jamie Laughlin's operations, this means reducing referral work and bringing more assays in-house to strengthen the lab's diagnostic services.

Moving to the fully automated cobas® i 601 analyser delivers the power of mass spec with core lab simplicity. Tiago Sousa, Biomedical Scientist at SWLP, highlights how random-access testing across a wide repertoire transforms complex assay workflows daily.

The cobas® Mass Spec solution has brought incredibly positive feedback from the SWLP team. By automating manual steps, the system allows laboratories to operate more efficiently, seamlessly bringing mass spectrometry into the automated core lab.